Zidovudine kinetics in the pregnant baboon

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 11, Issue 2, 1996, Pages 117-127

  Garland, Marianne ^a   Szeto, Hazel H ^b   Daniel, Salha S ^a   Tropper, Pamela J ^a   Myers, Michael M ^c   Stark, Raymond I ^a  

^a Columbia University ^*  (United States)

^b Department of Obstetrics Gynecology   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Baboon; Pharmacokinetics; Pregnancy; Primate; Zidovudine

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ARTICLE; BABOON; BLOOD PLACENTA BARRIER; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG METABOLISM; FETUS; GESTATIONAL AGE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MATERNAL PLASMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; PAPIO HAMADRYAS; PRIMATES;

EID: 0030034409     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199602010-00002     Document Type: Article

References (53)

1. Working Group of Siena Consensus Workshop. Report of a Consensus Workshop, Siena, Italy, January 17-18, 1992: maternal factors involved in mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 1992;5:1019-29.
2. Fast P, Newell M, Mofenson L, Ammann A, Rossi P, Siena Consensus Workshop II. Strategies for prevention of perinatal transmission of HIV infection. J Acquir Immune Defic Syndr 1995;8:161-75.
3. Mofenson LM, Wright PF, Fast PE. Summary of the Working Group on Perinatal Intervention. AIDS Res Hum Retroviruses 1992;8:1435-8.
4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
5. Van Rompay KK, Marthas ML, Ramos RA, et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992;36:2381-6.
6. Sharpe AH, Hunter JJ, Ruprecht RM, Jaenisch R. Maternal transmission of retroviral disease and strategies for preventing infection of the neonate. J Virol 1989;63:1049-53.
7. Toltzis P. Rationales for treating the human immunodeficiency virus-infected woman during pregnancy. Clin Perinatol 1993;20:47-60.
8. Szeto HH. Maternal-fetal pharmacokinetics: summary and future directions. NIDA Technical Rev 1995 (in press).
9. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebocontrolled trial. N Engl J Med 1987;317:185-91.
10. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988;319:889-96.
11. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986;1:575-80.
12. Schenker S, Johnson RF, King TS, Schenken RS, Henderson GI. Azidothymidine (zidovudine) transport by the human placenta. Am J Med Sci 1990;299:16-20.
13. Liebes L, Mendoza S, Wilson D, Dancis J. Transfer of zidovudine (AZT) by human placenta. J Infect Dis 1990;161:203-7.
14. Krauer B, Krauer F, Hytten FE. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther 1980;10:301-28.
15. Reynolds F, Knott C. Pharmacokinetics in pregnancy and placental drug transfer. Oxf Rev Reprod Biol 1989;11:389-449.
16. Stark RI, Daniel SS, James LS, et al. Chronic instrumentation and longterm investigation in the fetal and maternal baboon: tether system, conditioning procedures and surgical techniques. Lab Anim Sci 1989;39:25-32.
17. Wilkinson L. SYSTAT: the system for statistics. Evanston, IL: SYSTAT, 1988.
18. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-100.
19. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991;163:226-32.
20. Lopez-Anaya A, Unadkat JD, Schumann LA, Smith AL. Pharmacokinetics of zidovudine (azidothymidine). III, Effect of pregnancy. J Acquir Immune Defic Syndr 1991;4:64-8.
21. Herber R, Magdalou J, Haumont M, Bidault R, van Es H, Siest G. Glucuronidation of 3′-azido-3′-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones. Biochim Biophys Acta 1992;1139:20-4.
22. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol 1991;32:17-21.
23. Lauritzen C, Klopper A. Estrogens and androgens. In: Fuchs F, Klopper A, eds. Endocrinology of pregnancy. Philadelphia: Harper and Row, 1983:73-91.
24. Gerdin E, Spalding D, Lindberg B, Rane A. Glucuronidation of morphine and some drug oxidation reactions in liver microsomes from pregnant and non-pregnant rhesus monkeys. Pharmacol Toxicol 1991;69:78-80.
25. Agarwal RP, Mian AM. Thymidine and zidovudine metabolism in chronically zidovudine-exposed cells in vitro. Biochem Pharmacol 1991;42:905-11.
26. Blum MR, Liao SH, Good SS, de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988;85:189-94.
27. Tartaglione TA, Collier AC, Opheim K, Gianola FG, Benedetti J, Corey L. Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic immunodeficiency virus infection. Antimicrob Agents Chemother 1991;35:2225-31.
28. Mentre F, Escolano S, Diquet B, Golmard JL, Mallet A. Clinical pharmacokinetics of zidovudine: inter- and intraindividual variability and relationship to long-term efficacy and toxicity. Eur J Clin Pharmacol 1993;45:397-407.
29. Gallicano K, Sahai J, Ormsby E, Cameron DW, Pakuts A, McGilveray I. Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. Br J Clin Pharmacol 1993;36:128-31.
30. O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Am J Obstet Gynecol 1993;168:1510-6.
31. Laskin OL, de Miranda P, Blum MR. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. J Infect Dis 1989;159:745-7.
32. Klecker RW Jr, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987;41:407-12.
33. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989;110:279-85.
34. Patel BA, Boudinot FD, Schinazi FR, Gallo JM, Chu CK. Comparative pharmacokinetics and interspecies scaling of 3′-azicto-3′-deoxythymidine (AZT) in several mammalian species. J Pharmacobiodyn 1990;13:206-11.
35. Szeto HH. Pharmacokinetic studies in experimental animals. In: Reynold F, ed. Effects on the baby of maternal analgesia and anaesthesia. London: Saunders, 1993:29-45.
36. Sopelak VM, Hodgen GD. Techniques for research in fetal and neonatal primates. In: Nathanielsz PW, ed. Animal models in fetal medicine. Ithaca, NY: Perinatal Press, 1984;161-81.
37. Suomi SJ, Higley JD. Rationale and methodologies for developing nonhuman primate models of prenatal drug exposure. NIDA Res Monogr 1991;114:291-302.
38. Krauer B, Krauer F. Drug kinetics in pregnancy. Clin Pharmacokinet 1977;2:167-81.
39. Boudinot FD, Schinazi RF, Gallo JM, et al. 3′-Azido-2′,3′-dideoxyuridine (AzddU): comparative pharmacokinetics with 3′azido-3′-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses 1990;6:219-28.
40. Gallo JM, Finco TS, Swagler AR, Mehta MU, Viswanathan CT, Qian M. Pharmacokinetic evaluation of drug interactions with anti-HIV drugs. II. Effect of 2′,3′-dideoxyinosine (ddI) on zidovudine kinetics in monkeys. AIDS Res Hum Retroviruses 1992;8:277-83.
41. Good SS, Koble CS, Crouch R, Johnson RL, Rideout JL, de Miranda P. Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metab Dispos 1990;18:321-6.
42. Goland RS, Stark RI, Wardlaw SL. Responses to corticotropin-releasing hormone during pregnancy in the baboon. J Clin Endocrinol Metab 1990;70:925-9.
43. Goland RS, Wardlaw SL, Fortman JD, Stark RI. Plasma corticotropin-releasing factor concentrations in the baboon during pregnancy. Endocrinology 1992;131:1782-6.
44. Perry JS. The mammalian fetal membranes. J Reprod Fertil 1981;62:321-35.
45. Reynolds F, ed. Effects on the baby of maternal analgesia and anaesthesia. London: Saunders, 1993:282.
46. Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmaco-kinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:1541-7.
47. Stretcher BN, Pesce AJ, Hurtubise PE, Frame PT. Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. Ther Drug Monit 1992;14:281-5.
48. Pizzo P, Wilfert C, Pediatric AIDS Siena Workshop II. Markers and determinants of disease progression in children with HIV infection. J Acquir Immune Defic Syndr 1995;8:30-44.
49. Mayaux M, Blanche S, Rouzioux C, et al. Maternal factors associated with perinatal HIV-1 transmission: the French cohort study: 7 years of follow-up observation. J Acquir Immune Defic Syndr 1995;8:188-94.
50. Bredberg-Rådén U, Urassa W, Urassa E, et al. Predictive markers for mother-to-child transmission of HIV-1 in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 1995;8:182-7.
51. Temmerman M, Nyong'o A, Bwayo J, Fransen K, Coppens M, Piot P. Risk factors for mother-to-child transmission of human immunodeficiency virus-1 infection. Am J Obstet Gynecol 1995;172:700-5.
52. Lundgren B, Bottiger D, Ljungdahl-Stahle E, et al. Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr 1991;4:489-98.
53. McClure HM, Anderson DC, Ansari AA, Fultz PN, Klumpp SA, Schinazi RF. Nonhuman primate models for evaluation of AIDS therapy. Ann NY Acad Sci 1990;616:287-98.